Myalept

Chemical Namemetreleptin
Dosage FormInjection (subcutaneous; sterile, white, solid, lyophilized cake of 11.3 mg metreleptin per vial to deliver 5 mg per mL when reconstituted in 2.2 mL of BWFI or WFI)
Drug ClassHormones
SystemEndocrine
CompanyBristol-Myers Squibb
Approval Year2014

Indication

  • Used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myalept (metreleptin) Prescribing Information2014Bristol-Myers Squibb Company, Princeton, NJ